Vestronidase alfa: Recombinant human β-glucuronidase as an enzyme replacement therapy for MPS VII.

Abstract

Mucopolysaccharidosis VII (MPS VII) is a rare lysosomal storage disease characterized by a deficiency in the enzyme β-glucuronidase that has previously been successfully treated in a mouse model with enzyme replacement therapy. Here, we present the generation of a novel, highly sialylated version of recombinant human β-glucuronidase (rhGUS), vestronidase alfa, that has high uptake, resulting in an improved enzyme replacement therapy for the treatment of patients with MPS VII. In vitro, vestronidase alfa has 10-fold more sialic acid per mole of rhGUS monomer than a prior rhGUS version (referred to as GUS 43/44) and demonstrated very high affinity at ~1 nM half maximal uptake in human MPS VII fibroblasts. Vestronidase alfa has a longer enzymatic half-life after uptake into fibroblasts compared with other enzymes used as replacement therapy for MPS (40 days vs 3 to 4 days, respectively). In pharmacokinetic and tissue distribution experiments in Sprague-Dawley rats, intravenous administration of vestronidase alfa resulted in higher serum rhGUS levels and enhanced β-glucuronidase activity distributed to target tissues. Weekly intravenous injections of vestronidase alfa (0.1 mg/kg to 20 mg/kg) in a murine model of MPS VII demonstrated efficient enzyme delivery to all tissues, including bone and brain, as well as reduced lysosomal storage of glycosaminoglycans (GAGs) in a dose-dependent manner, resulting in increased survival after 8 weeks of treatment. Vestronidase alfa was well-tolerated and demonstrated no toxicity at concentrations that reached 5-times the proposed clinical dose. In a first-in-human phase 1/2 clinical trial, a dose-dependent reduction in urine GAG levels was sustained over 38 weeks of treatment with vestronidase alfa. Together, these results support the therapeutic potential of vestronidase alfa as an enzyme replacement therapy for patients with MPS VII.

• Authors: Jaclyn Cadaoas, Gabrielle Boyle, Steven Jungles, Sean Cullen, Michel Vellard, Jeffrey H Grubb, Agnieszka Jurecka, William Sly, Emil Kakkis
• Journal: Molecular genetics and metabolism (Mol Genet Metab) Vol. 130 Issue 1 Pg. 65-76 (05 2020) ISSN: 1096-7206 [Electronic] United States
• PMID: 32192868 (Publication Type: Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.

Chemical References

• Glycosaminoglycans
• Recombinant Proteins
• vestronidase alfa
• Glucuronidase

Topics

• Administration, Intravenous
• Adult
• Animals
• CHO Cells
• Child
• Cricetulus
• Enzyme Replacement Therapy (methods)
• Female
• Fibroblasts (metabolism)
• Glucuronidase (administration & dosage, blood, genetics, metabolism, pharmacokinetics)
• Glycosaminoglycans (metabolism, urine)
• Humans
• Lysosomes (enzymology, metabolism)
• Male
• Mice
• Mice, Transgenic
• Mucopolysaccharidosis VII (enzymology, therapy)
• Rats
• Rats, Sprague-Dawley
• Recombinant Proteins (genetics, metabolism)
• Tissue Distribution (drug effects)